The protective effect of canagliflozin on renal function in obese patients with T2DM
Not Applicable
- Conditions
- Obese T2DM with nephropathy
- Registration Number
- JPRN-UMIN000018711
- Lead Sponsor
- Division of Nephrology, Nippon Medical School
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
1) HbA1C >9.0% 2) Allergy to canagliflozin 3) Severe ketoacidosis or diabetic coma 4) severe infection, operation, and trauma 5)T1DM 6) Moderate to severe renal disfuction (eGFR <45ml/min/1.73m2) 7) Heart failure (NYHA IV) 8) possibility of hypoglycemia by canagliflozine such as hypopituitarism, adrenal insuficiency, excessive exercise, malnutition, excess alcohol intake. 9) Dehydration 10) severe liver disfunction (AST and ALT > 5 x normal range of the hospital) 11) Age more than 70 years 12) Age less than 20 years 13) Pregnant or breastfeeding mother 14) patients who was regarded as uneligible by the doctor
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change of eGFR slope
- Secondary Outcome Measures
Name Time Method Blood evaluation: HbA1c, eGFR, serum Cr, cystatin C, Uriva acid, T-chol, HDL-chol, TG Urine evaluation: ACR, 24hCCr, Urine volume, Na, K, Cl, L-FABP, B2-Mg, NAG, glucose and protein Blood pressure at office